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Aim: Lower urinary tract symptoms (LUTS) are a common urological referral,
which sometimes can have a neurological basis in a patient with no formally
diagnosed neurological disease (“occult neurology”). Early identification and
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specialist input is needed to avoid bad LUTS outcomes, and to initiate suitable
neurological management.
Methods: The International Continence Society established a neurological
working group to consider: Which neurological conditions may include LUTS
as an early feature? What diagnostic evaluations should be undertaken in the
LUTS clinic? A shortlist of conditions was drawn up by expert consensus and
discussed at the annual congress of the International Neurourology Society. A
multidisciplinary working group then generated recommendations for identi-
fying clinical features and management.
Results: The relevant conditions are multiple sclerosis, multiple system
atrophy, normal pressure hydrocephalus, early dementia, Parkinsonian syn-
dromes (including early Parkinson's Disease and Multiple System Atrophy)
and spinal cord disorders (including spina bifida occulta with tethered cord,
and spinal stenosis). In LUTS clinics, the need is to identify additional atypical
features; new onset severe LUTS (excluding infection), unusual aspects (eg,
enuresis without chronic retention) or “suspicious” symptoms (eg, numbness,
weakness, speech disturbance, gait disturbance, memory loss/cognitive im-
pairment, and autonomic symptoms). Where occult neurology is suspected,
healthcare professionals need to undertake early appropriate referral; central
nervous system imaging booked from LUTS clinic is not recommended.
Conclusions: Occult neurology is an uncommon underlying cause of LUTS,
but it is essential to intervene promptly if suspected, and to establish suitable
management pathways.
KEYWORD S
incontinence, lower urinary tract symptoms, neurology, neurourology, overactive bladder,
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1 | INTRODUCTION
Lower urinary tract symptoms (LUTS) are highly prevalent
and a major cause of urological referral. The majority reflect
uncomplicated presentations, such as overactive bladder
(OAB) or benign prostate enlargement. LUTS are also a
significant feature in neurological disease.1 Notably, there are
some neurological conditions where LUTS can be an early
symptom in the presentation of the disease. Consequently, a
situation can arise where LUTS assessment might be re-
quested and the underlying neurological disease is still un-
diagnosed. Two major dangers inherent in failing to identify
an undiagnosed neurological etiology are risks of deteriora-
tion of the neurological conditions, and of poor outcomes for
LUTS treatment, potentially due to inappropriate surgery or
symptom deterioration. Suitable neurological management
for the underlying condition is needed
• to establish a correct diagnosis and prognosis,
• to actively manage the neurological condition by ob-
taining early specialist input,
• to minimize disease progression through early treat-
ment (especially for multiple sclerosis [MS]),
• to avoid predictable adverse events during invasive
diagnostics and after surgical therapy,
• for the maintenance of a patient‐centered approach to
management, and
• for patients to adapt their life according to prognosis.
Healthcare professionals (HCPs) from various dis-
ciplines, notably doctors, nurses, continence advisors,
and physiotherapists, may be responsible for initial as-
sessment of these patients. Accordingly, these HCPs need
to remain alert to patients with subtle symptoms and
clinical signs that should be further explored and who
might need an additional referral to exclude or identify
an, as yet, undiagnosed neurological condition. For this
to be effective, they must be aware of potential pathways
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of evaluation, to ensure the possibility is appropriately
addressed.
This consensus considers situations where LUTS
could be a presenting complaint preceding the identifi-
cation of an underlying neurological disease,2 hereafter
referred to as “occult neurology.” This consensus docu-
ment gives brief outlines of neurological conditions in
which LUTS arise relatively early in the disease course,
and presents an approach to assessment of a patient
where the receiving clinician suspects there could be an
undiagnosed neurological condition.
2 | METHODS
The International Continence Society (ICS) established a
working group whose remit was to consider:
1. Which neurological conditions may include LUTS as
an early feature?
2. What diagnostic evaluations should be undertaken in
the LUTS clinic, and which should be left to specialist
expertise?
The qualitative method of nominal group technique
was utilized to generate initial content (key relevant
conditions) in response to the remit. An iterative group
dialogue for a panel of neurological and neurosurgical
specialists was used to draw up a shortlist of conditions,
with two rounds of blind voting to finalize the list.
The list was then presented for open discussion at
the annual congress of the International Neurourology
Society, Istanbul, 2020. The ICS then established
a multidisciplinary working group to generate re-
commendations for identifying clinical features and
management, which worked remotely due to the widely
dispersed international representation.
3 | RESULTS
3.1 | Neurological conditions where
LUTS can be an early feature
The following conditions may present for LUTS assess-
ment before a neurological condition has been re-
cognized, because LUTS are potentially an early feature
in the disease course. The underlying processes com-
monly involve demyelination, neurodegeneration, or de-
velopmental abnormality, for which some archetypal
conditions are listed in Table 1. The main conditions
responsible include the following.
3.1.1 | MS and related
neuroinflammatory disorders
The most common progressive neurological disease af-
fecting younger people with onset around 20 to 40 years
of age. It is more common in women than men. It can
impair function of any part of the central nervous system
by demyelination and axonal loss (Table 1). It is a pro-
gressive condition, but the rate and pattern of progression
varies (the progressive clinical course usually becoming
evident after 10‐20 years after diagnosis). Commonly,
there is abrupt deterioration (relapse) lasting days to
weeks as a new demyelination event starts, followed by
(often incomplete) improvement. Neurological symptoms
are typically monocular loss of vision, double vision,
sensory loss, weakness, and ataxia. A variety of disease‐
modifying medications are available. The exact pattern of
LUTS is diverse, while severe incontinence is mainly seen
in the late stages of the disease.
Transverse myelitis due to other inflammatory causes
can occasionally present as urinary retention with few
neurological signs because of predilection for conus in-
volvement, particularly when associated with antibodies
against Myelin oligodendrocyte glycoprotein (MOG an-
tibody transverse myelitis); persisting urogenital and bo-
wel dysfunction is common despite motor recovery at
followup.15
3.1.2 | Multiple system atrophy
A progressive sporadic adult‐onset neurodegenerative
disorder (Table 1). Prevalence is 8 per 100 000 among
people older than 40 years of age. It affects men and
women equally and has an average age onset of ap-
proximately 55 to 60 years. The mean life expectancy is
6 to 10 years following diagnosis. Clinical symptoms are
subdivided into extrapyramidal, pyramidal, cerebellar,
and autonomic symptoms (notably postural hypoten-
sion). Extrapyramidal symptoms include bradykinesia,
rigidity, and postural instability, resembling Parkinson's
disease (PD). Nonmotor symptoms, such as sleep and
cognitive disorders, respiratory problems, and emotional/
behavioral symptoms, might also occur during disease
development. The different symptoms can be used to
categorize multiple system atrophy (MSA) into the Par-
kinsonian subtype (MSA‐P) and the cerebellar subtype
(MSA‐C). MSA‐P predominates in Western countries,
while MSA‐C is more common in Japan. The condition
may initially present with bladder dysfunction, particu-
larly urinary retention.16,17 For men, erectile dysfunction
(ED)18 is commonly an earlier feature than LUTS; the
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reviewing HCP considering this possibility needs to en-
quire about ED, since men commonly do not report the
symptom unless the topic is raised.
3.1.3 | Parkinson's disease
A neurodegenerative condition with the key motor symp-
toms of tremor, rigidity, and bradykinesia affecting motor
control, which is also associated with prominent nonmotor
symptoms. Early PD can cause storage LUTS, and motor
symptoms may be mild. A useful feature to look out for is a
unilateral low frequency pill‐rolling tremor affecting the
upper limb (or leg). Established PD manifests obvious
motor features (shaking, rigidity, slowness of movement,
and difficulty with walking); once it has reached this stage,
PD will generally have been diagnosed.
PD patients usually report nocturia, urgency, and
difficulty voiding and present with detrusor overactivity
(DO) on urodynamics.19,20 Voiding dysfunction increases
with neurological disability (for men and women), cor-
relating with the extent of dopamine depletion.21,22 In
some male patients, benign prostatic obstruction can
occur concomitantly with PD, and therefore selection of
patient for possible prostate surgery should be done with
great care to avoid possible urinary incontinence.
3.1.4 | Normal pressure hydrocephalus
Normal pressure hydrocephalus (NPH) is characterized by
communicating enlargement of cerebrospinous fluid (CSF)
ventricles, with normal intraventricular pressures. The en-
largement is associated with stretching of periventricular
fibers of the corticospinal tract in the brain, which impairs
bladder control. DO is a typical finding on urodynamics. As
it is substantially underdiagnosed, the actual worldwide
incidence and prevalence have not been defined; in Japan it
was estimated at around 1% of older adults (over 65).23 The
classic triad is abnormal broad‐based shuffling gait, urinary
incontinence and dementia (short term memory impair-
ment), but about half present with gait abnormality only as
the initial feature. There may be only mild cognitive im-
pairment at the time the patient starts to experience urinary
symptoms. Treatment is with placement of a ven-
triculoperitoneal shunt by a neurosurgeon and can lead to
symptom resolution/prevention of progression.
3.1.5 | Dementia
A group of neurodegenerative conditions (including
Alzheimer's disease, vascular dementia, dementia with
Lewy bodies and frontotemporal dementia), with wide‐
ranging effects on memory, cognition, and personality.
LUTS are more common in people living with dementia
than those without dementia.24 In certain forms of de-
mentia, such as dementia with Lewy bodies, LUTS are
more likely to be an early feature of the disease. LUTS
tend to be a later feature in Alzheimer's disease.25
3.1.6 | Spinal cord conditions
A range of situations may affect the spinal cord directly
(Table 1), while degenerative spine conditions may affect
the spinal cord secondarily, for example, by causing
lumbar spinal stenosis or cervical myelopathy. There may
be little in the way of localizing symptoms. The arche-
typal condition is spina bifida occulta (SBO) and tethered
cord, in which a developmental abnormality fixes the
lower part of the spinal cord, placing it at risk by
stretching and distortion as the person grows. Affected
patients are often asymptomatic until late childhood or
adulthood, then presenting with back pain and LUTS.
Syringomyelia is a problem with the central CSF canal in
the spinal cord, which can lead to compression of the
surrounding spinal cord tracts; this can occur in SBO.
Other conditions include:
• a tumor of the spinal cord or vertebral column and
• spinal stenosis, leading to claudication and LUTS.
Prolapsed intervertebral disc (lumbar disc prolapse) is
usually easily diagnosed from the association of urinary
retention (painless) with severe back pain, nerve root
pain (eg, sciatica), loss of range of movement, and bowel
dysfunction. However, back pain is sometimes not pro-
minent, notably where there is central disc prolapse with
little impingement on the spinal roots.
3.2 | Evaluation where there is a
possible occult neurological mechanism
For the HCP, the fundamental issue is to identify a
situation where LUTS are present alongside other
unexplained symptoms, which are atypical for a LUTS
presentation. This must then trigger an onward re-
ferral to an appropriate specialist (neurology or neu-
rosurgery), or an alert to the patient's primary care
physician. HCPs in the LUTS clinic are not required to
make the neurological diagnosis, but they must remain
vigilant to the possibility of a neurological disorder
and seek relevant expertise (neurological consultation)
where needed.
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Situations in which HCPs should suspect possible
occult neurology:
• New onset severe LUTS not caused by urinary tract
infection.
• Association with unusual features not typically seen in
LUTS presentations.
• Presence of other “suspicious” symptoms, such as al-
tered speech, vision, or balance.
3.2.1 | History and examination
All consultations on LUTS involve a basic assessment
undertaken according to the relevant guidelines.18,26,27
The details of basic LUTS assessment are not given in
detail here, but guidelines include assessment of:
• Evaluation of the severity and bother associated with
each LUTS.
• Consideration of possible pathophysiology and differ-
ential diagnosis.
• Exclusion of features, which are possible indicators of
serious underlying mechanism, for example, infection/
inflammation, or malignancy.
• Concomitant bowel or sexual dysfunction.
Any neurological feature might, but not necessarily,
have a similar time course to the LUTS. If the initial im-
pression suggests there could be an occult neurological
problem, the practitioner should evaluate key indicators
that may increase the index of suspicion. A summary is
presented in Figure 1. This assessment includes looking for:
1. Urological symptoms or findings
(a) Severe/rapid onset OAB maybe with urgency
incontinence.
(b) Difficulty initiating voiding and prolonged dura-
tion. Flow rate test may suggest straining, and
there may be a post void residual.
(c) Changes in bladder sensation, including reduced
or absent bladder sensations.
(d) Dysuria in the absence of urinary tract infection
(this may indicate detrusor sphincter dyssynergia).
FIGURE 1 Summary of key clinical
evaluations in LUTS clinic in the event of a
possible undiagnosed neurological disease.
E, examination; ED, erectile dysfunction;
H, history; I, investigation; LUTS, Lower
urinary tract symptoms; RE, retrograde
ejaculation. *Flow rate test may suggest
straining/post void residual. **Double
vision/loss of acuity. Multiple sclerosis can
cause transient unilateral loss of vision
some years previously. ***Nerve supply is
from the sacral spinal cord, and is a
consequence of weak plantar flexion and
dorsiflexion
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2. Unusual urological symptoms or examination findings
(a) Enuresis.
(b) Voiding dysregulationm, that is, urination in si-
tuations, which are generally regarded as socially
inappropriate, such as while still fully dressed, or
in a public setting away from toilet facilities.28
(c) Involuntary voiding, that is, sporadic bladder
emptying when awake, without intention to
void.28
3. Indicators of lower urinary tract muscle weakness
(a) Abdominal straining for voiding.
(b) Stress urinary incontinence (and possibly fecal
incontinence), particularly in nulliparous women
and younger men with no previous lower urinary
tract surgery.
(c) Retrograde ejaculation.
4. Symptoms or findings in other organ systems, which
are heavily dependent on neurological control or likely
to be affected by a relevant condition
(a) Gastrointestinal, for example gastroparesis, con-
stipation, reduced anal tone.
(b) Cardiovascular for example orthostatic hypotension.
(c) Musculoskeletal.
(d) Autonomic, for example loss of salivation, loss of
sweating, and impaired thermoregulation. In PD
and MSA there may be drooling (sialorrhoea).
5. Features of one of the neurological conditions listed
above
(a) MS; motor or sensory deficit, transient unilateral
visual disturbance (previous optic neuritis).
(b) MSA; ED, orthostatic hypotension, unilateral tre-
mor, slow movement, postural instability.
(c) PD; Stooped posture, lack of facial expression,
quiet and hoarse speech, slowness of movement
especially visible during walking, and shaking
(tremor)—more often seen unilaterally in the
hand while walking or at rest and classically “pill‐
rolling” in nature.
(d) NPH; gait disturbance, urinary incontinence,
cognitive impairment.
(e) Dementia; memory and personality changes.
(f) Spinal cord problem; limb weakness, sensory
changes, back pain.
Observation of or assessment for gait, tremor, speech,
and clumsiness can easily be made in clinic. It is worth
noting any history of essential tremor, as this might be
confused with a parkinsonian tremor, but does not need
neurology referral. Essential tremor typically presents
with bilateral postural hand tremor and can also affect
the head and voice, has a family history, and improves
with beta blockers or alcohol.
3.3 | Additional assessment for possible
neurological disease
In the event that history and examination are consistent
with the possibility of occult neurological disease, the
responsible practitioner needs to considerthe following.
1. Steps to confirm or exclude the neurological diagnosis:
(a) The HCP treating LUTS should refer for a formal
specialist opinion. Direct referral is preferable, for
reliable and prompt assessment.
(b) The consensus panel does not recommend the use
of MRI scanning or other imaging modality from
the LUTS clinic. This is best arranged from the
neurology clinic, in consultation between the
neurology and neuroradiology services, because it
is crucial that the correct part of the neuraxis is
scanned and the appropriate settings are used.
(c) The referral should be made immediately, without
waiting for the results of urodynamic testing (due
to the potential delay). If urodynamics have al-
ready been done, the results can be included in the
referral. Subsequent urodynamic tests can be for-
warded when available.
(d) Neurological consultation and investigation fol-
lowing referral may not necessarily attain a con-
firmatory diagnosis; urological follow up is
nonetheless appropriate, and re‐referral to neu-
rology may be needed in the event of subsequent
change in symptoms or apparent deterioration.
2. Adaptations of the urological assessment pathway:
(a) The role of urodynamic testing should be re‐
evaluated; if not already done, they may be de-
layed pending receipt of the neurological evalua-
tion, to decide how the test should be run. In this
situation, it is appropriate that the test is directly
overseen by the urologist.
(b) Definitive LUTS management should be delayed
until the result of neurological assessment is
available. If the neurological finding is positive,
the patient should be moved to a neuro‐urological
care pathway for example.1,29 If negative, standard
LUTS pathways can be followed, but this should
be reconsidered if new symptoms subsequently
emerge.
3.4 | Additional considerations
In several situations, factors affecting lower urinary tract
function may be suggested by features in the medical
history or physical examination:
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1. Functional neurological disorder (FND)30 is suggested
by symptoms such as limb weakness and nonepileptic
attacks, particularly in women with chronic idiopathic
urinary retention. FNDs may be accompanied by
psychological comorbidities such as affective disorders
(eg, depression and anxiety) and other functional
syndromes, such as fibromyalgia or irritable bowel
syndrome. Screening tools are available for evaluating
psychological/psychiatric morbidities in adults.30
2. Centrally active medications may cause urinary re-
tention (eg, opioids, antipsychotics, antidepressant
agents, anticholinergic respiratory agents, alpha‐
adrenoceptor agonists and benzodiazepines31) or en-
uresis (eg, choline esterase inhibitors (such as rivas-
tigmine or, donepezil) and antipsychotics32).
3. Scrutiny of medical history and current medication, to
consider conditions that may already be diagnosed in
the patient, but whose implication for LUTS has not
been recognized. Potentially relevant conditions in-
clude (list not complete):
(a) Previous pelvic or retroperitoneal surgery (in case of
damage to peripheral lower urinary tract nerves).
This may make the patient reliant on abdominal
straining for bladder emptying.
(b) Delayed second stage of labor (pudendal nerve damage).
(c) Previous traumatic brain injury.
(d) Previous spine hyperextension without fracture.
(e) Neuropathies for example vitamin B12 deficiency,
diabetic neuropathy (but not uncomplicated diabetes
mellitus), systemic lupus erythematosus, Sjogren's
syndrome, amyloid, myasthenia gravis, or Guillain
Barre syndrome. Severe peripheral neuropathies can
cause gait disturbance with sensory ataxia.
(f) Herpes zoster infection of sacral dermatomes with
shingles (this is very rare).
(g) Active genital herpes affecting sacral levels.
If any of these is identified, they should be considered
in case they represent a contributory factor underlying
LUTS. If they appear to be causative:
• The possibility of occult neurological disease is re-
duced, and the priority of neurological assessment
should be reviewed accordingly.
• The urological assessment should be designed to reflect
the complexity of the LUTS mechanisms.
4 | CONCLUSIONS
There is a large catalog of neurological diseases, but
relatively few affect urinary tract function early in their
course. MS, MSA, PD, NPH, some types of dementia or
specific spinal cord pathologies are particularly relevant.
Thus, an HCP seeing a patient with LUTS should re-
main alert to features indicating the possibility of an
underlying neurological condition. If suspected, specia-
list input should be sought before requesting diagnostic
imaging, and the LUTS management pathway should be
adapted.
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